TGTX Stock Overview
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
TG Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$18.93 |
52 Week High | US$23.12 |
52 Week Low | US$6.46 |
Beta | 2.23 |
11 Month Change | 3.39% |
3 Month Change | 16.92% |
1 Year Change | 69.02% |
33 Year Change | -22.58% |
5 Year Change | 174.35% |
Change since IPO | 1,566.00% |
Recent News & Updates
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12Recent updates
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Shareholder Returns
TGTX | US Biotechs | US Market | |
---|---|---|---|
7D | -5.3% | -1.0% | 0.3% |
1Y | 69.0% | 16.3% | 18.6% |
Return vs Industry: TGTX exceeded the US Biotechs industry which returned 17.2% over the past year.
Return vs Market: TGTX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
TGTX volatility | |
---|---|
TGTX Average Weekly Movement | 6.6% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 14.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TGTX's share price has been volatile over the past 3 months.
Volatility Over Time: TGTX's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 284 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
TGTX fundamental statistics | |
---|---|
Market cap | US$2.83b |
Earnings (TTM) | US$41.20m |
Revenue (TTM) | US$289.33m |
65.8x
P/E Ratio9.4x
P/S RatioIs TGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TGTX income statement (TTM) | |
---|---|
Revenue | US$289.33m |
Cost of Revenue | US$18.72m |
Gross Profit | US$270.62m |
Other Expenses | US$229.42m |
Earnings | US$41.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.29 |
Gross Margin | 93.53% |
Net Profit Margin | 14.24% |
Debt/Equity Ratio | 63.5% |
How did TGTX perform over the long term?
See historical performance and comparison